{"id":"https://openalex.org/W2010977040","doi":"https://doi.org/10.1016/s0968-0896(01)00110-9","title":"Structure\u2013activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor","display_name":"Structure\u2013activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor","alternate_titles":[],"publication_year":2001,"publication_date":"2001-08-01","ids":{"openalex":"https://openalex.org/W2010977040","doi":"https://doi.org/10.1016/s0968-0896(01)00110-9","mag":"2010977040","pmid":"https://pubmed.ncbi.nlm.nih.gov/11504634"},"language":"en","primary_location":{"id":"doi:10.1016/s0968-0896(01)00110-9","doi":"https://doi.org/10.1016/s0968-0896(01)00110-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0968-0896(01)00110-9","pdf_url":null,"source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic &amp; Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2010977040"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029592350","display_name":"H\u00e9l\u00e8ne J\u00fbteau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H\u00e9l\u00e8ne Juteau","raw_affiliation_strings":["Merck Frosst Canada & Co., Pointe-Claire-Dorval, H9R 4P8, Qu\u00e9bec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., Pointe-Claire-Dorval, H9R 4P8, Qu\u00e9bec, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089543390","display_name":"Yves Gareau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Yves Gareau","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113871113","display_name":"Marc Labelle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marc Labelle","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034868328","display_name":"Claudio F. Sturino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Claudio F Sturino","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074907384","display_name":"Nicole Sawyer","orcid":"https://orcid.org/0000-0001-5270-6556","observed_orcids":["https://orcid.org/0000-0001-5270-6556"]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicole Sawyer","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111997509","display_name":"Nathalie M. Tremblay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nathalie Tremblay","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038978966","display_name":"Sonia Lamontagne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sonia Lamontagne","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085670473","display_name":"Marie\u2010Claude Carri\u00e8re","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marie-Claude Carri\u00e8re","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110035588","display_name":"Danielle Denis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Danielle Denis","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077798378","display_name":"Kathleen M. Metters","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kathleen M Metters","raw_affiliation_strings":["Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Qu\u00e9bec, Canada H9R 4P8","institution_ids":["https://openalex.org/I4210095507"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5089543390"],"corresponding_institution_ids":["https://openalex.org/I4210095507"],"apc_list":{"value":3960,"currency":"USD","value_usd":3960},"apc_paid":null,"fwci":1.2955,"has_fulltext":false,"cited_by_count":131,"citation_normalized_percentile":{"value":0.78683652,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"9","issue":"8","first_page":"1977","last_page":"1984"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.6782000064849854,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.6782000064849854,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.09809999912977219,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.058800000697374344,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.8460000157356262},{"id":"https://openalex.org/keywords/receptor-antagonists","display_name":"receptor antagonists","score":0.8429999947547913},{"id":"https://openalex.org/keywords/human-serum-albumin","display_name":"human serum albumin","score":0.7429999709129333},{"id":"https://openalex.org/keywords/binding-affinity","display_name":"binding affinity","score":0.7070000171661377},{"id":"https://openalex.org/keywords/sulfonamide-analogues","display_name":"sulfonamide analogues","score":0.8550000190734863}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.9090009331703186},{"id":"https://openalex.org/C2778266237","wikidata":"https://www.wikidata.org/wiki/Q962217","display_name":"Prostanoid","level":3,"score":0.8378130197525024},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.7620470523834229},{"id":"https://openalex.org/C2778597219","wikidata":"https://www.wikidata.org/wiki/Q11721976","display_name":"Human serum albumin","level":2,"score":0.5363373160362244},{"id":"https://openalex.org/C178592051","wikidata":"https://www.wikidata.org/wiki/Q28208812","display_name":"Prostaglandin E2 receptor","level":4,"score":0.4895659387111664},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.4268789291381836},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.42404043674468994},{"id":"https://openalex.org/C114373084","wikidata":"https://www.wikidata.org/wiki/Q273499","display_name":"Chemical synthesis","level":3,"score":0.4181879758834839},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41390323638916016},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4045274257659912},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2828981578350067},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.17818063497543335},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D002934","descriptor_name":"Cinnamates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002934","descriptor_name":"Cinnamates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011448","descriptor_name":"Prostaglandin Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011448","descriptor_name":"Prostaglandin Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D018078","descriptor_name":"Receptors, Prostaglandin E","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018078","descriptor_name":"Receptors, Prostaglandin E","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D058308","descriptor_name":"Receptors, Prostaglandin E, EP3 Subtype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/s0968-0896(01)00110-9","doi":"https://doi.org/10.1016/s0968-0896(01)00110-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0968-0896(01)00110-9","pdf_url":null,"source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic &amp; Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:11504634","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11504634","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8199999928474426,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1533085687","https://openalex.org/W1557741015","https://openalex.org/W1776234781","https://openalex.org/W1972643685","https://openalex.org/W1974801475","https://openalex.org/W1981665452","https://openalex.org/W1995657296","https://openalex.org/W1999291449","https://openalex.org/W2048009051","https://openalex.org/W2063136699","https://openalex.org/W2063908349","https://openalex.org/W2063924884","https://openalex.org/W2077104835","https://openalex.org/W2084615605","https://openalex.org/W2090040898","https://openalex.org/W2092547841","https://openalex.org/W2107574924","https://openalex.org/W2121612337","https://openalex.org/W2258579859","https://openalex.org/W2325970742","https://openalex.org/W2953108508","https://openalex.org/W4238437238"],"related_works":["https://openalex.org/W2911959948","https://openalex.org/W2177356077","https://openalex.org/W1990976846","https://openalex.org/W2032083732","https://openalex.org/W2071408538","https://openalex.org/W2174493882","https://openalex.org/W2063849128","https://openalex.org/W2056897790","https://openalex.org/W2005583283","https://openalex.org/W1966059107"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2010977040","counts_by_year":[{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":12},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
